Table 5.

Cox regression of incident ILD while on first HER2-directed therapy among patients without prevalent ILD at index, n = 398

Variable	P-value	HR (95% CI)	N	N events
Age > 65 years	0.926	1 (0.4, 2.3)	94	7
Black/African-American	0.002	3.4 (1.6, 7.5)	79	12
BMI: overweight (25–30)	0.274	0.5 (0.2, 1.6)	105	6
BMI: obese (30+)	0.783	0.9 (0.4, 2.2)	137	12
Ever smoker	0.037	2.2 (1.1, 4.8)	168	17
Prior lung comorbidities	0.124	1.8 (0.9, 3.8)	195	19
Prior thoracic radiation	0.143	2.3 (0.8, 7.1)	30	4
Prior ILD-inducing systemic therapies	0.145	0.5 (0.2, 1.3)	122	5
Less than 1 month from first metastasis to index	0.185	1.7 (0.8, 3.5)	183	16
ECOG: > 0	0.266	1.8 (0.6, 5.1)	97	9

BMI body mass index, CI confidence interval, ECOG Eastern Collaborative Oncology Group, HR hazard ratio, ILD interstitial lung disease, N number